An unexpected phaeochromocytoma represents one of the most serious events in anaesthesia, and unless well managed, carries a very high mortality. Although the problem is not common, anaesthetists may be faced with an unexpected phaeochromocytoma either in intensive care, or as a complication of almost any surgical procedure. Phaeochromocytoma is frequently undiagnosed as it may present with a bewildering array of symptomatology (Table I ) and patients may be normotensive or even hypotensive, depending on the nature and expression of the tumour. Preoperative absence of symptoms does not exclude the diagnosis. Patients may also present with a variety of medical emergencies. The most hazardous presentation is that of phaeochromocytoma multisystem crisis which carries a very high mortality.
The most important factor in making the diagnosis of an unexpected phaeochromocytoma is thinking of it. All too frequently, fatal cases have not been diagnosed until it's too late, or even at post mortem. Any unexplained hypotensive event occurring during anaesthesia must raise consideration of a phaeochromocytoma, particularly if associated with unusual abdominal symptoms or the sudden onset of pulmonary oedema or cardiac failure. A number of drugs that are normally not associated with hypertension may precipitate a phaeochromocytoma, while unexpected hypertensive events associated with the administration of steroids, metoclopramide, phenothiazines, ionic contrast material or beta blockers should alert the clinician to the possibility.
Intraoperative
For the anaesthetist, the most common situation that presents is where a phaeochromocytoma crisis arises during anaesthesia for an apparently unrelated problem. This can occur during any type of surgery, but the possibility must always be considered in patients with atypical bowel problems, particularly apparent bowel ischaemia or obstruction, both of which can be induced by excess catecholamines. A hypertensive event occurring during exploratory surgery for undiagnosed abdominal mass must always raise the possibility of a phaeochromocytoma crisis. Hypertension on induction of anaesthesia is always suspicious, but personal experience suggests that the hypertensive event frequently occurs during the procedure, particularly once surgery has commenced. Where a hypertensive event is followed by a hypotensive crisis, the most likely explanation becomes a phaeochromocytoma, although stress-induced myocardial ischaemia may also give a similar picture. As the event occurs, the surgeon should be notified immediately and any surgical procedure halted until diagnosis can be established.
When an intraoperative crisis occurs, the anaesthetist must rapidly consider alternative differential diagnoses. A patient presenting with an acute onset of hypertension and increased metabolic rate may be suffering from sepsis (which should be obvious), thyrotoxicosis, malignant hyperthermia or a phaeochromocytoma crisis. These may be difficult to distinguish in an emergency situation, but some guidelines can be obtained from Table II . Immediate investigation should include consideration of oxygen consumption rates (available on most modern anaesthetic machines), body temperature measurement and arterial blood gas. It is critical to remember that the core temperature may increase quite late in the course of malignant hyperthermia.
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When phaeochromocytoma crisis is diagnosed, immediate management should consist of an intravenous bolus of 2 g MgSO 4 which can be repeated at five-minute intervals until adequate haemodynamic control is established. 2 Even if the hypertensive crisis has proceeded to cardiac failure with pulmonary oedema and impaired cardiac output, magnesium remains a good agent, since the immediate need is to reduce peripheral vasoconstriction. Even in the presence of a tachycardia with arrhythmias, betablockade must never be considered as the firstline therapy as there is a high risk that it will worsen the condition. If myocardial ischaemia is present, magnesium should still be the first-line therapeutic agent and, once vasodilatation has been established, careful introduction of beta-blockade can be considered. Ideally, esmolol should be the drug of choice under these circumstances. While labetolol may be regarded as a suitable agent because of its combined alpha-and beta-adrenergic blocking effects, the beta-blocking effect predominates and acute cardiac failure has been reported when this agent has been used in phaeochromocytomas. 3 Indeed, unexplained cardiopulmonary dysfunction after the administration of beta-blockade should immediately raise the possibility of an undiagnosed phaeochromocytoma, or alternatively cocaine toxicity or other alpha-adrenergic drug administration. 4 Sodium nitroprusside, nifedipine or phentolamine may be considered as alternatives to magnesium, but none of them is as readily available, or as easy to administer.
Once the diagnosis of phaeochromocytoma is assumed, invasive monitoring should immediately be established, with the placement of an arterial line, together with central venous cannulation, to allow central administration of drugs. A rapid decision must now be made regarding the surgical situation. Where surgery is considered to be life saving, for example in acute abdomen with bowel ischaemia, it may be necessary to proceed with the operation, bearing in mind that the diagnosis may change given that the phaeochromocytoma crisis can present with a clinical If abdominal surgery has already commenced and the tumour is obviously and immediately available for removal, it may be advisable to proceed to tumour excision, bearing in mind that severe hypovolaemia and hypotension are likely to follow tumour removal. Aggressive volume replacement is likely to be required and plasma expansion with colloid is probably the best option in these circumstances, preferably guided by some form of cardiac performance monitor such as an oesophageal Doppler flow probe or pulse waveform analysis. Where the tumour is not available for immediate excision, the procedure should be abandoned, and the patient stabilised in an intensive care unit, and then referred for formal diagnosis and preoperative preparation as for an elective phaeochromocytoma. 6 Whether or not the tumour is excised immediately, the patient must be transferred to an intensive care unit following surgery, as haemodynamic instability is likely to be considerable in the postoperative period of the unprepared patient.
A specific presentation that must never be overlooked is the occurrence of a phaeochromocytoma crisis during pregnancy. Such an event carries a 40% maternal mortality and a 56% foetal mortality, 7 but the diagnosis is notoriously difficult. 8 Phaeochromocytoma in pregnancy can mimic a number of disease processes, most notably severe pre-eclampsia and pregnancyinduced cardiomyopathy. Failure to make a correct diagnosis early in the course of the disease carries a grave prognosis. Key pointers that would suggest a phaeochromocytoma, particularly in late pregnancy, include sudden onset of hypertension in a previously normotensive patient, occurrence of hypertension and glycosuria, since elevated blood sugar is not a feature of pre-eclampsia, and the development of respiratory problems, particularly pulmonary oedema, prior to delivery, which is unusual with pre-eclampsia. 9 The development of cardiac failure in late pregnancy as a result of phaeochromocytoma carries a grave prognosis and the majority of reported cases have died within 24 hours of the onset of symptoms. All of these deaths had evidence of catecholamine-induced cardiomyopathy. 10 The absence of hyperreflexia may assist in differentiating these cases from severe pre-eclampsia, although visual symptoms and convulsions may still occur.
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Once the diagnosis is made, treatment must be with MgSO 4 , as it will be effective in both pre-eclampsia and in phaeochromocytoma. Where severe tachycardia coexists with hypertension, a combination of magnesium and labetolol has been described as effective, but a beta blocker should not be administered if catecholamine-induced cardiomyopathy is suspected. In this situation, magnesium alone has been described as being highly effective in reversing the depressed myocardial performance. 2 The decision as to when the mother should deliver will depend on the circumstances and level of local expertise. In early pregnancy, up to 32 weeks, the best strategy is probably haemodynamic stabilisation with doxazocin or (preferably) phenoxybenzamine, followed by elective tumour removal. If the tumour is small and can be resected through a laparoscopic approach, this carries relatively low risk for the foetus, although the risk is not negligible. If the crisis presents in labour, the ideal management is less clear. Haemodynamic stabilisation with appropriate invasive monitoring should be established rapidly and, provided the foetus remains viable, early Caesarean section should be performed, preferably after anaesthesia. Whether or not simultaneous resection of the phaeochromocytoma should be undertaken at this time will depend on a number of factors, including the expertise on offer, the health of the mother after delivery, and availability of intensive care facilities.
